All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
The question of inherited susceptibility to Multiple Myeloma (MM) and genetic background of familial MM has long gone unanswered. In April 2017, Britt-Marie Halvarsson and Bjorn Nilsson from The Department of Laboratory Medicine, Lund University, Lund, Sweden, and collaborators, published a paper in Blood Advances, in which they demonstrated an enrichment of common MM risk alleles in familial MM compared with sporadic MM.
In conclusion, a direct association between polygenic etiology in MM was identified, but future sequencing efforts of larger populations are required for further clarity. Limitations of the study were the small sample size, which did not allow exome-wide screening for rare mutations, and the fact that cases of monoclonal gammopathy of unknown significance (MGUS) were not recorded in the registry.
Although common risk alleles for multiple myeloma (MM) were recently identified, their contribution to familial MM is unknown. Analyzing 38 familial cases identified primarily by linking Swedish nationwide registries, we demonstrate an enrichment of common MM risk alleles in familial compared with 1530 sporadic cases (P = 4.8 × 10−2 and 6.0 × 10−2, respectively, for 2 different polygenic risk scores) and 10 171 population-based controls (P = 1.5 × 10−4 and 1.3 × 10−4, respectively). Using mixture modeling, we estimate that about one-third of familial cases result from such enrichments. Our results provide the first direct evidence for a polygenic etiology in a familial hematologic malignancy.
References
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?